Literature DB >> 28732563

Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.

Shih-Wen Ting1, Chen-Hsiang Lee2, Jien-Wei Liu3.   

Abstract

BACKGROUND/
PURPOSE: A substantial number of carbapenem-resistant Gram-negative bacilli (CR GNB) have been identified among the etiologic multidrug-resistant GNB in healthcare-associated infections. For achieving a better therapeutic outcome by minimizing inappropriate empirical antibiotic treatment before blood culture and susceptibility testing results are available, it is very important to identify patients who are at risk for the development of CR GNB bacteremia.
METHODS: Retrospective analysis of propensity-score matched (PSM) adult patients with CR GNB bacteremia (PSM-group 1 [n = 95]) and those with non-CR GNB bacteremia (PSM-group 2 [n = 190]).
RESULTS: PSM-group 1 was found to a significantly longer length of hospital stay (27 vs. 18 days; p < 0.001) after emerging GNB bacteremia and a higher 30-day all-cause mortality rate (27.4% vs. 5.8%; p < 0.001), when compared with PSM-2 group. Independent risk factors for the acquisition of CR GNB bacteremia were previous exposure to an antipseudomonal penicillin (odds ratio [OR] = 3.58; 95% confidence interval [CI] = 1.30-9.90), an antipseudomonal cephalosporin (OR = 3.49; 95% CI = 1.09-11.24), and a carbapenem (OR = 3.60; 95% CI = 1.37-9.47), and longer length of hospital stay before the development of GNB bacteremia (OR = 1.03; 95% CI = 1.01-1.05).
CONCLUSION: Risk factors for acquisition of CR GNB bacteremia identified in this study each may serve as a reminder alerting clinicians to hospitalized patients at risk for CR GNB bacteremia requiring appropriate antibiotic coverage, and in these circumstances, combined antibiotics may be used until antimicrobial de-escalation/adjustment is clearly indicated by the subsequently identified pathogenic GNB and its susceptibility profile.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Bacteremia; Carbapenem-resistant; Gram-negative bacillus; Outcomes; Propensity-matched; Risk factors

Mesh:

Substances:

Year:  2017        PMID: 28732563     DOI: 10.1016/j.jmii.2016.08.022

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  12 in total

1.  Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.

Authors:  Jien-Wei Liu; Yen-Hsu Chen; Wen-Sen Lee; Jung-Chung Lin; Ching-Tai Huang; Hsi-Hsun Lin; Yung-Ching Liu; Yin-Ching Chuang; Hung-Jen Tang; Yao-Shen Chen; Wen-Chien Ko; Min-Chi Lu; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Tigecycline Therapy for Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Critically Ill Patients.

Authors:  Wen-Liang Yu; Nan-Yao Lee; Jann-Tay Wang; Wen-Chien Ko; Chung-Han Ho; Yin-Ching Chuang
Journal:  Antibiotics (Basel)       Date:  2020-05-05

Review 3.  Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms.

Authors:  Nan-Yao Lee; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Front Pharmacol       Date:  2019-10-04       Impact factor: 5.810

4.  Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016.

Authors:  Chun-Hsing Liao; Na-Yao Lee; Hung-Jen Tang; Susan Shin-Jung Lee; Chin-Fu Lin; Po-Liang Lu; Jiunn-Jong Wu; Wen-Chien Ko; Wen-Sen Lee; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2019-03-04       Impact factor: 4.003

5.  Increased financial burdens and lengths of stay in patients with healthcare-associated infections due to multidrug-resistant bacteria in intensive care units: A propensity-matched case-control study.

Authors:  Li-Hsiang Su; I-Ling Chen; Ya-Fen Tang; Jen-Sin Lee; Jien-Wei Liu
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

6.  Formulation and evaluation of injectable dextran sulfate sodium nanoparticles as a potent antibacterial agent.

Authors:  Osama A Madkhali; Sivakumar Sivagurunathan Moni; Muhammad H Sultan; Haitham A Bukhary; Mohammed Ghazwani; Nabil A Alhakamy; Abdulkarim M Meraya; Saeed Alshahrani; Saad Saeed Alqahtani; Mohammed Ali Bakkari; M Intakhab Alam; Mohamed Eltaib Elmobark
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

7.  Comparison of Risk Factors and Outcomes in Carbapenem-Resistant and Carbapenem-Susceptible Gram-Negative Bacteremia.

Authors:  Sinan Cetin; Ilyas Dokmetas; Aziz Ahmad Hamidi; Banu Bayraktar; Alper Gunduz; Dilek Yildiz Sevgi
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-09-24

8.  Rapid Determination of Antibiotic Resistance in Klebsiella pneumoniae by a Novel Antibiotic Susceptibility Testing Method Using SYBR Green I and Propidium Iodide Double Staining.

Authors:  Yabin Zhang; Weihua Fan; Chunhong Shao; Jiajia Wang; Yan Jin; Jing Shao; Ying Zhang; Yong Wang
Journal:  Front Microbiol       Date:  2021-06-09       Impact factor: 5.640

9.  Risk factors for and clinical outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia.

Authors:  Dong Hoon Shin; Dong-Yeop Shin; Chang Kyung Kang; Suhyeon Park; Jieun Park; Kang Il Jun; Taek Soo Kim; Youngil Koh; Jun Shik Hong; Pyoeng Gyun Choe; Wan Beom Park; Nam-Joong Kim; Sung-Soo Yoon; Inho Kim; Myoung-Don Oh
Journal:  BMC Infect Dis       Date:  2020-06-09       Impact factor: 3.090

10.  Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study.

Authors:  Elisangela M Lima; Patrícia A Cid; Debora S Beck; Luiz Henrique Z Pinheiro; João Pedro S Tonhá; Marcio Z O Alves; Newton D Lourenço; Roberto Q Santos; Marise D Asensi; José Aurélio Marques; Carolina S Bandeira; Caio Augusto S Rodrigues; Saint Clair S Gomes Junior; Marisa Z R Gomes
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-14       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.